Merck & Co., Inc. is 93.9x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($294.13 B vs $3.13 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ARQT | MRK |
|---|---|---|
| Market cap | $3.13 B | $294.13 B |
| US-listed rank | #1773 | #44 |
| Revenue (latest FY) | $376.07M | $65.01B |
| Net income (latest FY) | -$16.14M | $18.25B |
| Net margin | -4.3% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 798 | 996 |
Merck & Co., Inc. is 93.9x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($294.13 B vs $3.13 B).
In their latest fiscal years, Arcutis Biotherapeutics, Inc. reported $376.07M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Arcutis Biotherapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.